Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Dec 3, 2022

Keywords

ClinConnect Summary

This clinical trial is looking to understand how certain cell clusters from tumors can help predict if women with early-stage endometrial cancer will respond well to treatment with progesterone. This is important for women who wish to preserve their fertility and keep their uterus. The study is currently recruiting participants who are female, aged between 18 and 60, and have been diagnosed with either atypical endometrial hyperplasia or a specific type of early-stage endometrial cancer without signs of spread beyond the uterus.

To join the trial, participants must be willing to maintain their reproductive function and follow treatment plans closely. However, those with severe liver or kidney issues, pregnant women, or those with other significant health problems may not qualify. Participants can expect to undergo testing that helps doctors understand their individual response to treatment, which may ultimately guide more personalized care for women facing this diagnosis. This trial is a step towards better treatment options while still considering the desire for future pregnancies.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Have a confirmed pathological diagnosis based upon hysteroscopy: atypical endometrial hyperplasia or histologically prove well-differentiated EEC G1 without myometrial invasion
• • No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound
• • Have a desire for remaining reproductive function or uterus
• • Good compliance with adjunctive treatment and follow-up
• Exclusion Criteria:
• • Acute liver disease or liver tumor (benign or malignant) or renal dysfunction
• • Pregnancy or potential pregnancy
• • Confirmed diagnosis of any cancer in reproductive system
• • Acute severe disease such as stroke or heart infarction or a history of thrombosis disease
• • Hypersensitivity or contradiction for using MPA or MA
• • With other factors of reproductive dysfunction;
• • Strong request for uterine removal or other conservative treatment